We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

The Good, the Bad, and the Ugly of Free Drug Samples

Kenneth A. Katz, MD, MSc, MSCE1; Erika E. Reid, MD2; Mary-Margaret Chren, MD3,4
[+] Author Affiliations
1Department of Dermatology, The Permanente Medical Group Inc, Pleasanton, California
2Department of Dermatology, University of Pennsylvania, Philadelphia
3Department of Dermatology, University of California, San Francisco
4San Francisco Veterans Affairs Medical Center, San Francisco, California
JAMA Dermatol. 2014;150(11):1238. doi:10.1001/jamadermatol.2014.1815.
Text Size: A A A
Published online


In Reply We agree with Dr Poligone that evidence should guide the practice of medicine. With respect to dispensing free drug samples, existing evidence supports our contention that this practice should be discouraged in dermatology.

Although the prescribing practices of Dr Poligone’s colleague are laudable, they are the exception, not the rule, when it comes to drug samples. Indeed, a substantial and growing body of evidence1,2 (including the study on which we commented3) has shown that physicians who give patients drug samples are more likely than other physicians to prescribe medicines that are more expensive and less appropriate as first-line treatments. Moreover, drug samples are more likely to be newer and therefore more likely to have emerging safety concerns, including concerns that lead to black-box warnings.4


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





November 1, 2014
Brian Poligone, MD, PhD
1Department of Dermatology, University of Rochester School of Medicine, Rochester, New York
JAMA Dermatol. 2014;150(11):1237-1238. doi:10.1001/jamadermatol.2014.1820.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...